 | • レポートコード：GIR-2104Z04114 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、嚢胞性線維症（CF）治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。嚢胞性線維症（CF）治療の種類別市場規模（膵臓酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTRモジュレーター）、用途別市場規模（経口薬、吸入薬）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・嚢胞性線維症（CF）治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Vertex Pharmaceuticalsorporated、Gilead、AbbVie,、Novartis AG、F. Hoffmann-La Roche Ltd、Alaxia、Merck & Co.、AIT (Advanced Inhalation Therapies)、ALLERGAN、AstraZeneca、Teva Pharmaceutical Industries Ltd、Alcresta ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：膵臓酵素サプリメント、粘液溶解薬、気管支拡張薬、CFTRモジュレーター ・用途別分析2016年-2026年：経口薬、吸入薬 ・嚢胞性線維症（CF）治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・嚢胞性線維症（CF）治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・嚢胞性線維症（CF）治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・嚢胞性線維症（CF）治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・嚢胞性線維症（CF）治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Cystic Fibrosis (CF) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Cystic Fibrosis (CF) Therapeutics size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Cystic Fibrosis (CF) Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Cystic Fibrosis (CF) Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Pancreatic enzyme supplements
Mucolytics
Bronchodilators
CFTR modulators
Market segment by Application, can be divided into
Oral drugs
Inhaled drugs
Market segment by players, this report covers
Vertex Pharmaceuticalsorporated
Gilead
AbbVie,
Novartis AG
F. Hoffmann-La Roche Ltd
Alaxia
Merck & Co.
AIT (Advanced Inhalation Therapies)
ALLERGAN
AstraZeneca
Teva Pharmaceutical Industries Ltd
Alcresta
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Cystic Fibrosis (CF) Therapeutics
1.2 Classification of Cystic Fibrosis (CF) Therapeutics by Type
1.2.1 Overview: Global Cystic Fibrosis (CF) Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type in 2020
1.2.3 Pancreatic enzyme supplements
1.2.4 Mucolytics
1.2.5 Bronchodilators
1.2.6 CFTR modulators
1.3 Global Cystic Fibrosis (CF) Therapeutics Market by Application
1.3.1 Overview: Global Cystic Fibrosis (CF) Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Oral drugs
1.3.3 Inhaled drugs
1.4 Global Cystic Fibrosis (CF) Therapeutics Market Size & Forecast
1.5 Global Cystic Fibrosis (CF) Therapeutics Market Size and Forecast by Region
1.5.1 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Cystic Fibrosis (CF) Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Cystic Fibrosis (CF) Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Cystic Fibrosis (CF) Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Cystic Fibrosis (CF) Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Cystic Fibrosis (CF) Therapeutics Market Drivers
1.6.2 Cystic Fibrosis (CF) Therapeutics Market Restraints
1.6.3 Cystic Fibrosis (CF) Therapeutics Trends Analysis
2 Company Profiles
2.1 Vertex Pharmaceuticalsorporated
2.1.1 Vertex Pharmaceuticalsorporated Details
2.1.2 Vertex Pharmaceuticalsorporated Major Business
2.1.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.1.4 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Vertex Pharmaceuticalsorporated Recent Developments and Future Plans
2.2 Gilead
2.2.1 Gilead Details
2.2.2 Gilead Major Business
2.2.3 Gilead Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.2.4 Gilead Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Gilead Recent Developments and Future Plans
2.3 AbbVie,
2.3.1 AbbVie, Details
2.3.2 AbbVie, Major Business
2.3.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.3.4 AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 AbbVie, Recent Developments and Future Plans
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.4.4 Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis AG Recent Developments and Future Plans
2.5 F. Hoffmann-La Roche Ltd
2.5.1 F. Hoffmann-La Roche Ltd Details
2.5.2 F. Hoffmann-La Roche Ltd Major Business
2.5.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.5.4 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
2.6 Alaxia
2.6.1 Alaxia Details
2.6.2 Alaxia Major Business
2.6.3 Alaxia Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.6.4 Alaxia Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Alaxia Recent Developments and Future Plans
2.7 Merck & Co.
2.7.1 Merck & Co. Details
2.7.2 Merck & Co. Major Business
2.7.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.7.4 Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Merck & Co. Recent Developments and Future Plans
2.8 AIT (Advanced Inhalation Therapies)
2.8.1 AIT (Advanced Inhalation Therapies) Details
2.8.2 AIT (Advanced Inhalation Therapies) Major Business
2.8.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.8.4 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 AIT (Advanced Inhalation Therapies) Recent Developments and Future Plans
2.9 ALLERGAN
2.9.1 ALLERGAN Details
2.9.2 ALLERGAN Major Business
2.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.9.4 ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 ALLERGAN Recent Developments and Future Plans
2.10 AstraZeneca
2.10.1 AstraZeneca Details
2.10.2 AstraZeneca Major Business
2.10.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.10.4 AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 AstraZeneca Recent Developments and Future Plans
2.11 Teva Pharmaceutical Industries Ltd
2.11.1 Teva Pharmaceutical Industries Ltd Details
2.11.2 Teva Pharmaceutical Industries Ltd Major Business
2.11.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.11.4 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.12 Alcresta
2.12.1 Alcresta Details
2.12.2 Alcresta Major Business
2.12.3 Alcresta Cystic Fibrosis (CF) Therapeutics Product and Solutions
2.12.4 Alcresta Cystic Fibrosis (CF) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Alcresta Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Cystic Fibrosis (CF) Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Cystic Fibrosis (CF) Therapeutics Players Market Share
3.2.2 Top 10 Cystic Fibrosis (CF) Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Cystic Fibrosis (CF) Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Cystic Fibrosis (CF) Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Cystic Fibrosis (CF) Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Cystic Fibrosis (CF) Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2026)
6.2 North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2026)
6.3 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country
6.3.1 North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2026)
7.2 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2026)
7.3 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country
7.3.1 Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Region
8.3.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Region (2016-2026)
8.3.2 China Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2026)
9.2 South America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2026)
9.3 South America Cystic Fibrosis (CF) Therapeutics Market Size by Country
9.3.1 South America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country
10.3.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Cystic Fibrosis (CF) Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Cystic Fibrosis (CF) Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Cystic Fibrosis (CF) Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Cystic Fibrosis (CF) Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Cystic Fibrosis (CF) Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Vertex Pharmaceuticalsorporated Corporate Information, Head Office, and Major Competitors
Table 7. Vertex Pharmaceuticalsorporated Major Business
Table 8. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 9. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Gilead Corporate Information, Head Office, and Major Competitors
Table 11. Gilead Major Business
Table 12. Gilead Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 13. Gilead Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. AbbVie, Corporate Information, Head Office, and Major Competitors
Table 15. AbbVie, Major Business
Table 16. AbbVie, Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 17. AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 19. Novartis AG Major Business
Table 20. Novartis AG Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 21. Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors
Table 23. F. Hoffmann-La Roche Ltd Major Business
Table 24. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 25. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Alaxia Corporate Information, Head Office, and Major Competitors
Table 27. Alaxia Major Business
Table 28. Alaxia Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 29. Alaxia Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Merck & Co. Corporate Information, Head Office, and Major Competitors
Table 31. Merck & Co. Major Business
Table 32. Merck & Co. Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 33. Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. AIT (Advanced Inhalation Therapies) Corporate Information, Head Office, and Major Competitors
Table 35. AIT (Advanced Inhalation Therapies) Major Business
Table 36. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 37. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. ALLERGAN Corporate Information, Head Office, and Major Competitors
Table 39. ALLERGAN Major Business
Table 40. ALLERGAN Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 41. ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 43. AstraZeneca Major Business
Table 44. AstraZeneca Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 45. AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Teva Pharmaceutical Industries Ltd Corporate Information, Head Office, and Major Competitors
Table 47. Teva Pharmaceutical Industries Ltd Major Business
Table 48. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 49. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Alcresta Corporate Information, Head Office, and Major Competitors
Table 51. Alcresta Major Business
Table 52. Alcresta Cystic Fibrosis (CF) Therapeutics Product and Solutions
Table 53. Alcresta Cystic Fibrosis (CF) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Cystic Fibrosis (CF) Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 55. Global Cystic Fibrosis (CF) Therapeutics Revenue Share by Players (2019-2021)
Table 56. Breakdown of Cystic Fibrosis (CF) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Cystic Fibrosis (CF) Therapeutics Players Head Office, Products and Services Provided
Table 58. Cystic Fibrosis (CF) Therapeutics Mergers & Acquisitions in the Past Five Years
Table 59. Cystic Fibrosis (CF) Therapeutics New Entrants and Expansion Plans
Table 60. Global Cystic Fibrosis (CF) Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 61. Global Cystic Fibrosis (CF) Therapeutics Revenue Share by Type (2016-2021)
Table 62. Global Cystic Fibrosis (CF) Therapeutics Revenue Forecast by Type (2021-2026)
Table 63. Global Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2021)
Table 64. Global Cystic Fibrosis (CF) Therapeutics Revenue Forecast by Application (2021-2026)
Table 65. North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Cystic Fibrosis (CF) Therapeutics Picture
Figure 2. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Type in 2020
Figure 3. Pancreatic enzyme supplements
Figure 4. Mucolytics
Figure 5. Bronchodilators
Figure 6. CFTR modulators
Figure 7. Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Application in 2020
Figure 8. Oral drugs Picture
Figure 9. Inhaled drugs Picture
Figure 10. Global Cystic Fibrosis (CF) Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Cystic Fibrosis (CF) Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Region (2016-2026)
Figure 13. Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America Cystic Fibrosis (CF) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Cystic Fibrosis (CF) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Cystic Fibrosis (CF) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Cystic Fibrosis (CF) Therapeutics Market Drivers
Figure 19. Cystic Fibrosis (CF) Therapeutics Market Restraints
Figure 20. Cystic Fibrosis (CF) Therapeutics Market Trends
Figure 21. Vertex Pharmaceuticalsorporated Recent Developments and Future Plans
Figure 22. Gilead Recent Developments and Future Plans
Figure 23. AbbVie, Recent Developments and Future Plans
Figure 24. Novartis AG Recent Developments and Future Plans
Figure 25. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
Figure 26. Alaxia Recent Developments and Future Plans
Figure 27. Merck & Co. Recent Developments and Future Plans
Figure 28. AIT (Advanced Inhalation Therapies) Recent Developments and Future Plans
Figure 29. ALLERGAN Recent Developments and Future Plans
Figure 30. AstraZeneca Recent Developments and Future Plans
Figure 31. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Figure 32. Alcresta Recent Developments and Future Plans
Figure 34. Global Cystic Fibrosis (CF) Therapeutics Revenue Share by Players in 2020
Figure 35. Cystic Fibrosis (CF) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Cystic Fibrosis (CF) Therapeutics Revenue Market Share in 2020
Figure 37. Global Top 10 Players Cystic Fibrosis (CF) Therapeutics Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Cystic Fibrosis (CF) Therapeutics Revenue Share by Type in 2020
Figure 40. Global Cystic Fibrosis (CF) Therapeutics Market Share Forecast by Type (2021-2026)
Figure 41. Global Cystic Fibrosis (CF) Therapeutics Revenue Share by Application in 2020
Figure 42. Global Cystic Fibrosis (CF) Therapeutics Market Share Forecast by Application (2021-2026)
Figure 43. North America Cystic Fibrosis (CF) Therapeutics Sales Market Share by Type (2016-2026)
Figure 44. North America Cystic Fibrosis (CF) Therapeutics Sales Market Share by Application (2016-2026)
Figure 45. North America Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 46. United States Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Cystic Fibrosis (CF) Therapeutics Sales Market Share by Type (2016-2026)
Figure 50. Europe Cystic Fibrosis (CF) Therapeutics Sales Market Share by Application (2016-2026)
Figure 51. Europe Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 52. Germany Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Region (2016-2026)
Figure 60. China Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Cystic Fibrosis (CF) Therapeutics Sales Market Share by Type (2016-2026)
Figure 67. South America Cystic Fibrosis (CF) Therapeutics Sales Market Share by Application (2016-2026)
Figure 68. South America Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Cystic Fibrosis (CF) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の嚢胞性線維症（CF）治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Cystic Fibrosis Therapeutics Market The global Cystic Fibrosis Therapeutics market size is projected to reach US$ 11170 million by 2026, from US$ 4551.4 million in 2019, at a CAGR of 13.5% during 2021-2026. With industry-standard accuracy in analysis and high dat…- 世界の嚢胞性線維症（ムコビスコイドーシス）検査市場規模・現状・予測（2021年-2027年） Cystic Fibrosis, also known as mucoviscoidosis, is an inherited genetic disorder that affects the secretory glands, including mucus and sweat glands. It mainly affects the lungs and digestive system. An individual suffering from cystic fibrosis show characteristic symptoms, such as, secretion of thi…
- 世界の腎線維化治療市場 2021：企業別、地域別、種類・用途別 The Kidney Fibrosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regul…
- 世界の膵臓がん治療薬市場規模・現状・予測（2021年-2027年） Pancreatic cancer therapy is recommended by clinicians for early detection of cancer. Pancreatic cancer generally diagnosed at a later stage, since the symptoms are not easily detected or diagnosed. Factors such as, chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity …
- 世界の外分泌膵機能不全（EPI）市場規模・現状・予測（2021年-2027年） Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, am…